No products in the cart.
Pre-made Alacizumab benchmark antibody ( di-Fab, anti-KDR therapeutic antibody, Anti-FLK1/CD309/VEGFR/VEGFR2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-014
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab’)2 fragment of a monoclonal antibody.
| Products Name (INN Index) | Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody |
|---|---|
| INN Name | Alacizumab |
| Target | KDR |
| Format | di-Fab |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2007 |
| Year Recommended | 2008 |
| Companies | UCB |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Non-small cell lung cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | KDR |
| Package |
Previous slide
Next slide
